![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 35, 24726-24730, August 27, 1999
From the Deoxyguanosine kinase (dGK) is a nuclear gene
product that catalyzes the phosphorylation of purine
deoxyribonucleosides and their analogues. The human enzyme is located
predominantly in the mitochondria, as shown by biochemical
fractionation studies and in situ localization of the
overexpressed recombinant protein. Here we describe the cloning of
mouse dGK cDNA and the identification of a novel amino-terminally
truncated isoform that corresponds to about 14% of the total dGK
mRNA population in mouse spleen. In situ fluorescence
assays suggest that the new isoform cannot translocate into the
mitochondria and thus may represent a cytoplasmic enzyme. Expression of
mouse dGK mRNA was highly tissue-specific and differed from the
tissue distribution observed in humans. Recombinant mouse dGK showed
similar specific activity and substrate specificity as compared with
the human enzyme. The broad specificity, restricted tissue
distribution, and location of mouse dGK in multiple cellular
compartments raise new considerations with respect to the role of the
individual deoxynucleoside kinases in nucleotide metabolism.
In mammalian cells, the synthesis of
dNTP1 precursors for nuclear
DNA synthesis is performed by two pathways: (a) the de
novo pathway, and (b) the salvage pathway. The
rate-limiting step in the de novo pathway, which involves
the initial synthesis of ribonucleotides from ribose-5-phosphate, amino
acids, and CO2, is the irreversible removal of the
2'-hydroxyl group from ribonucleotide diphosphates, catalyzed by
ribonucleotide reductase (1). The alternative pathway for dNTP
synthesis involves phosphorylation of deoxynucleosides derived from
either endogenous dNTP breakdown or their uptake from the extracellular
space. In this pathway, the rate-limiting reaction is the first
phosphorylation step catalyzed by cytoplasmic deoxynucleoside kinases
(2). Because the dNTP pools produced by both pathways are in rapid
equilibrium, the actual contribution of the de novo or
salvage pathway for nuclear DNA synthesis depends on several factors
such as cell type, cell cycle, or the physiological state of the cell
(3, 4).
In contrast to the nucleus, the inner membrane of the mitochondria is
impermeable to charged molecules such as deoxyribonucleotides. There is
no definitive evidence for the existence of enzymes involved in the
de novo pathway inside the mitochondria. Therefore, the main
supply of dNTPs for DNA synthesis in this organelle seems to be
deoxynucleoside salvage regulated by two recently cloned mitochondrial
enzymes: (a) deoxyguanosine kinase (dGK), and (b) thymidine kinase (TK)-2 (5-8). Human dGK can efficiently phosphorylate deoxyguanosine and deoxyadenosine, whereas TK2 phosphorylates deoxyadenosine and deoxycytidine (5-8). This suggests that the combined action of the two enzymes is sufficient for the synthesis of
all four dNTPs for mitochondrial DNA replication. Human dGK and dCK
have overlapping but not identical substrate specificities toward both
natural substrates and therapeutic nucleoside analogues (5, 6, 9-11).
For example, certain analogues, such as 2',2'-difluorodeoxyguanosine, are phosphorylated mainly by dGK, whereas others, such as
2-chloro-2'-deoxyadenosine or
9- Here we report the cloning, expression, and functional characterization
of mouse dGK cDNA. We present evidence for the expression of a
cytoplasmic isoform of mouse dGK. This activity may play a role in dNTP
synthesis for nuclear DNA replication or repair. In addition, it may
have important implications in the evaluation of the contribution of
mitochondrial or nuclear DNA damage induced by certain drugs in mouse models.
Isolation of Mouse dGK cDNA Clones--
Approximately 1 × 106 plaques of a mouse spleen cDNA library in
RNA Analysis--
Total RNAs from different mouse tissues were
prepared by the guanidinium-isothiocyanate extraction method (12) and
separated on formaldehyde containing 1% agarose gel (12). After
capillary transfer to nitrocellulose membranes, the blot was hybridized with the cDNA probe encompassing the entire mdGK-1 cDNA as
described above. For RNase protection, the 1-185-nt region of mdGK-2
was amplified by the polymerase chain reaction and subcloned into Bluescript vector. Antisense riboprobe synthesis and RNase protection with mouse spleen poly(A) RNA was performed as described previously (13). The intensities of radioactive signals were quantitated by a
phosphorimager (Bio-Rad GS525).
Expression, Purification, and Enzyme Assay of Recombinant
dGK--
The coding region of the mouse and human dGKs was amplified
using a set of primers containing NcoI (5' end) and
BamHI (3' end) restriction sites. The polymerase chain
reaction products were digested with NcoI and
BamHI and subcloned into the pET-9d prokaryotic expression
vector (Novagen), which provides a 6× His fusion tag under the control
of the bacterial T7 promoter. Protein expression was induced in the
Escherichia coli BL21 (DE3) pLysS strain by treatment with 1 mM isopropyl-1-thio- Enzyme Assays--
The activities of recombinant mouse and human
dGK were compared by phosphoryl transfer assay using
[32P]ATP as the phosphate donor and various nucleosides
as phosphate acceptors. Reaction mixtures contained 50 mM
Tris-HCl, pH 7.6, 5 mM MgCl2, 5 mM
dithiothreitol, 0.5 mg/ml bovine serum albumin, 15 mM NaF,
0.4 mM [32P]ATP, 7.5 ng of purified enzyme,
and 5 or 100 µM nucleoside substrate. Reaction mixtures
were incubated at 37 °C for 20 min, and reactions were stopped by
heating at 100 °C for 2 min. The phosphorylated products were
separated by polyethyleneimine thin layer chromatography and quantified
as described previously (14).
Detection of dGK-GFP Fusion Proteins in Mammalian Cells--
The
coding regions of mdGK-1 and mdGK-2 were subcloned into the
NheI and XhoI site of the pEGFP-N1
(CLONTECH) vector to generate in-frame
carboxyl-terminal fusions with GFP cDNA under the control of the
cytomegalovirus promoter. The resulting constructs were used for
transient transfections of Cos-1 cells by the calcium phosphate
coprecipitation method (15). 24 h after transfection, the
intracellular localization of GFP fusion proteins in live cells was
observed by fluorescence microscopy in a Leitz Dialux 20 EB microscope
equipped with epifluorescence optics (15).
We have screened a mouse spleen cDNA library with the human
dGK cDNA probe and isolated six positive clones. Sequence analysis revealed two types of clones, mdGK-1 and mdGK-2. The mdGK-1 cDNA sequence contained a 831-nt-long open reading frame encoding a protein
of 277 amino acids with a predicted molecular mass of 32 kDa (Fig.
1). The amino acid sequence exhibited a
75% identity to human dGK, with 58 conservative and 11 nonconservative
amino acid substitutions throughout the coding region. Amino acid
changes were most frequent at the amino-terminal region containing the mitochondrial translocation signal sequence (20 substitutions out of 39 amino acids), whereas certain domains such as the putative ATP binding
site, the substrate specificity site, and the arginine-rich domain
were almost identical (Fig. 1). These motifs are highly conserved in
several deoxynucleoside kinases of different species (16), underlining
their functional significance.
The nucleotide sequence of the mdGK-2 clone was identical to mdGK-1
cDNA from nucleotide position 43 (which corresponds to nt 14 of
mdGK-1) throughout the rest of its coding and 3'-untranslated region
(Fig. 2). However, the sequence
divergence in the 5' end region eliminates the first ATG codon found in
mdGK-1, generating an open reading frame starting from a downstream ATG
codon that corresponds to amino acid position 32 of mdGK-1. The two
in-frame stop codons in the divergent part of mdGK-2 exclude the
possibility of potential start sites upstream of the cloned cDNA
(Fig. 2). mdGK-2 cDNA therefore encodes an amino-terminally
truncated isoform of dGK, lacking the first 31 amino acids of the
putative mitochondrial signal sequence. Although it contains some of
the amino acids of the consensus mitochondrial cleavage site (Fig. 2),
the characteristic feature of most mitochondrial targeting sequences,
an upstream
Cloning and Characterization of Mouse Deoxyguanosine Kinase
EVIDENCE FOR A CYTOPLASMIC ISOFORM*
§,
,
Institute of Molecular Biology and
Biotechnology, Foundation for Research and Technology Hellas, P. O. Box 1527, 711 10 Herakleion Crete, Greece and the ¶ Department of
Veterinary Medical Chemistry, The Biomedical Center, S-751 23 Uppsala, Sweden
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
-D-arabinofuranosyl-guanine, are substrates for both
dCK and dGK. These characteristics are important for understanding the
toxic side effects of some widely used anti-viral drugs and raise a new
concept regarding the development of drugs specifically targeted to
interfere with mitochondrial DNA replication. An in-depth understanding
of the regulation and biochemical properties of this enzyme is
therefore of particular interest, not only in its basic biological
aspect, but also for further pharmacological exploitation.
![]()
MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
ggt11 (CLONTECH) were screened with a cDNA
probe encompassing the entire coding region of human dGK (5).
Hybridization was performed overnight at 65 °C in 6× saline/sodium
phosphate/EDTA (1× saline/sodium phosphate/EDTA = 0.15 M NaCl and 10 mM sodium phosphate/1
mM EDTA), 5× Denhardt's solution (1× Denhardt's
solution = 0.02% each of bovine serum albumin,
polyvinylpyrrolidone, and Ficoll), 0.1% SDS, 100 µg/ml salmon sperm
DNA, and 106 cpm/ml radiolabeled probe. The filters were
subsequently washed four times with 2× SSC/0.1% SDS and once with
0.2× SSC/0.1% SDS at 65 °C. Positive plaques were purified, and
the cDNA inserts were subcloned into the EcoRI site of
Bluescript vector. DNA sequences from both strands were determined by
an automatic laser fluorescent sequencer (ABI).
-D-galactopyranoside for
3 h at 37 °C. The cells were lysed by sonication in a buffer containing 20 mM Tris-HCl, pH 8.0, 200 mM NaCl,
0.5% Triton X-100, 5 mM imidazole, and 1 mM
phenylmethylsulfonyl fluoride, and the recombinant proteins were
purified by affinity chromatography on a TALON
(CLONTECH) metal affinity column as described
previously (5). The eluted proteins were dialyzed in a buffer
containing 50 mM Tris-HCl, pH 7.5, 10 mM NaF, 2 mM dithiothreitol, 20% glycerol, and 1 mM
phenylmethylsulfonyl fluoride and used for SDS-polyacrylamide gel
electrophoresis analysis (12) and enzyme assays.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

View larger version (44K):
[in a new window]
Fig. 1.
The nucleotide and deduced amino acid
sequence of mouse dGK-1 cDNA. Amino acids in bold
indicate altered residues as compared with the human dGK sequence (5,
6). The highly conserved regions in different viral and mammalian
deoxynucleoside kinases are boxed. The black
arrow indicates the potential mitochondrial peptide cleavage
site.
-helical region followed by a stretch of positively
charged amino acids (17, 18), is absent. This raised the possibility
that mdGK-2 may encode a cytoplasmic isoform of dGK. To confirm this possibility, we investigated the subcellular localization of mdGK-1 and
mdGK-2. Two plasmids were constructed to express mdGK-1 and mdGK-2 as
fusion proteins with the GFP. The GFP moiety was inserted into the
carboxyl-terminal part to avoid interference with the amino-terminal
signal sequence. Fluorescence microscopy of transiently transfected
Cos-1 cells revealed dramatic differences in the localization of the
two fusion proteins. Transfection of mdGK-1-GFP gave rise to several
dot-like fluorescent structures in a nonfluorescent cytoplasmic
background (Fig. 3), characteristic of
the mitochondrial location of proteins (19, 20). In contrast,
transfection of mdGK-2-GFP produced a diffused fluorescent signal
throughout the cytoplasm (Fig. 3). In both cases, no fluorescence was
detected in the nucleus. These data strongly suggest that mdGK-2, even when overexpressed, does not translocate into the mitochondria.

View larger version (16K):
[in a new window]
Fig. 2.
Sequence comparison of the amino-terminal
region of mdGK-1 and mdGK-2. The nucleotide sequence of mdGK-2
cDNA is identical to mdGK-1 from nt position 43. The divergent
upstream sequence eliminates the first ATG codon of mdGK-1, placing the
translation initiation site at the downstream ATG at nt position
130. Asterisks indicate in-frame stop codons in the 5' end
of mdGK-2. The presumed consensus motif and the site for mitochondial
cleavage (18) are indicated by bold letters and
an arrow, respectively.

View larger version (20K):
[in a new window]
Fig. 3.
Analysis of intracellular localization of
mdGK-1 and mdGK-2. Fluorescent images of live Cos-1 cells
transfected with pEGFP-N1 (GFP), pEGFP-N1-mdGK-1
(mdGK-1-GFP), and pEGFP-N-1-mdGK-2 (mdGK-2-GFP)
are shown. The expected diffuse fluorescent signal in all cellular
compartments is seen with GFP alone, whereas mdGK-1-GFP and mdGK-2-GFP
show patterns characteristic of mitochondrial and cytoplasmic proteins,
respectively.
We next examined the expression pattern of mouse dGK in different
tissues. Northern blot analysis of total RNAs with the coding region of
mdGK-1 showed a broad band around 1.3 kb in all tissues tested (Fig.
4). However, the relative strength of the
signals varied greatly, suggesting clear tissue-specific differences in dGK expression. The highest levels were observed in the spleen and
thymus, whereas much lower levels of dGK mRNA were detected in the
brain and liver (Fig. 4).
|
To determine the expression levels of mdGK-2 relative to mdGK-1, we
performed a RNase protection experiment using highly purified poly(A)
mRNA from mouse spleen, where dGK mRNA was most abundant. A
194-nt-long antisense riboprobe containing the 1-185-bp region of
mdGK-2 cDNA was synthesized, which should give rise to a 185-bp protected fragment when hybridized to mdGK-2 mRNA and to a 142-bp fragment when hybridized to mdGK-1 mRNA. The results of this assay demonstrate a substantial expression of the mdGK-2 isoform, which accounts for about 14% of the total dGK (mdGK-1 + mdGK-2) mRNA population (Fig. 5).
|
For biochemical characterization of mouse dGK, we expressed its
cDNA as well as its human counterpart in E. coli as 6×
His-tagged fusion proteins. The histidine tag allowed a one-step
affinity purification of the recombinant proteins, giving highly pure
products of ~33 kDa as judged by SDS-gel electrophoresis (data not
shown). The phosphoryl transfer assay was used to compare the
activities of the human and mouse dGK using various substrates. The
substrate specificity of mouse dGK was similar to that of the human
enzyme (Table I). Both enzymes
phosphorylate deoxyguanosine, deoxyadenosine, and their analogues at
both low (5 µM) and high (100 µM)
concentrations. The phosphorylation of the cytostatic nucleoside
analogues 2-chloro-2-deoxyadenosine, 2',2'-difluorodeoxyguanosine, and
2'-2-fluoro-9-
-D-arabinofuranosyladenine was achieved to
about the same extent with both enzymes. The anti-human immunodeficiency virus compound 2',3'-dideoxyinosine was also phosphorylated to about 10% of that of deoxyguanosine at a
physiological concentration. The major difference observed here was
that the human enzyme showed a greater affinity toward deoxyadenosine
and was able to phosphorylate deoxycytidine at a high substrate
concentration. Both enzyme preparations showed specific activities
similar to that reported previously for the human dGK enzyme (5).
|
| |
DISCUSSION |
|---|
|
|
|---|
An important property of all four mammalian deoxynucleoside kinases, especially in the case of the enzyme family comprising dCK, dGK, and TK2, is their broad substrate specificity (16). This enabled the development of a large number of anti-cancer and anti-viral nucleoside analogues whose metabolism to their active cytotoxic forms depends on the activity of these enzymes. The need for the establishment of relevant animal models is enormous because most of our knowledge of dNTP metabolic pathways and their pharmacological exploitation comes from studies using immortalized cell lines. A prerequisite of such models is to compare the main biochemical properties of the enzymes involved between different species. Human and mouse TK1 or TK2 appear to have similar substrate specificities against several deoxyribonucleoside analogues (21). In contrast, significant differences in the capacity to phosphorylate a number of substrates were observed between human and mouse dCK (21, 22).
In the present study, we have cloned and analyzed the mouse homologue of dGK as an initial step to compare its biochemical properties and contribution to dNTP metabolism with those of its human counterpart. The amino acid sequence of mouse dGK showed a 75% identity to human dGK, significantly lower than the identity observed between mouse and human TK1 (87%) (23) or dCK (94%) (22). This suggests a lower selective pressure on the dGK coding region that may relate to its functional redundancy. On the other hand, all motifs initially identified in herpesvirus thymidine kinases and subsequently found in dCK and TK2 (24, 25) are highly conserved. These include the putative ATP binding site, the substrate recognition site, and the arginine-rich site (Fig. 1). Therefore, the substrate preferences of deoxynucleoside kinases should depend on their different active conformations, determined in part by other, less conserved regions. We found similar specificities between mouse and human dGK for most of the substrates studied. This information, together with careful comparative sequence analyses of the less conserved regions, will help to design domain swapping and site-directed mutagenesis experiments to elucidate the structural basis of the overlapping but not identical substrate specificities of these enzymes.
The high variations of dGK mRNA in different mouse tissues suggest different cell type-specific requirements for this enzyme. dGK mRNA levels were highest in mouse spleen and thymus and were very low in the brain and liver. This pattern is similar to the previously reported expression pattern of mouse dCK mRNA, which was shown to be most abundant in lymphoid tissues and relatively rare in other tissues (22). This finding suggests that the expression of the two enzymes is not regulated to compensate for each other but rather to provide increased rates of salvage biosynthesis in certain cell types.
dGK has been considered to be located exclusively in the mitochondria. This assumption is based on two important findings: (a) the highest dGK enzyme activity was found in purified mitochondrial extracts (26), and (b) human dGK cDNA contained a functionally active mitochondrial targeting sequence (6, 27). In this study, we found that mouse spleen cells express an unusual mRNA species of dGK (mdGK-2) whose open reading frame codes for an amino-terminally truncated, active isoform that lacks a mitochondrial signal peptide. The perfect identity with mdGK-1 in the rest of the sequence corroborates the idea that this isoform is probably generated by an alternative splicing mechanism. When expressed as a GFP fusion protein, mdGK-2 cannot enter the mitochondria, suggesting that it represents a cytoplasmic isoform of dGK.
Although the majority of the mouse spleen dGK mRNA population
(86%) encodes for the characteristic mitochondrial isoform (mdGK-1), the amount (14%) of the truncated isoform coding mRNA (mdGK-2) is
high enough to suggest a significant functional importance. It is
interesting to note that the cDNA isolated for the other mitochondrial kinase, human TK2, also lacks a mitochondrial signal sequence (7, 8). Although the structure of full-length TK2 cDNA
remains to be determined, the reported TK2 cDNAs may also represent
true non-mitochondrial isoforms rather than simply corresponding to
partial cDNA clones. The expression of a cytoplasmic dGK raises several concerns with respect to our view of dNTP metabolism. It may
participate in the supply of purine deoxynucleotides for nuclear DNA
replication and repair. In this way, nucleoside analogues phosphorylated by dGK may exert their cytotoxic effects by interference with both mitochondrial and nuclear DNA synthesis. The location of dCK
(28) and some of dGK in the cytoplasm also raises speculations of
potential heterodimer formation between the two proteins that may
generate novel enzyme properties. The recent identification of a
functional mitochondrial dCTP carrier protein adds a further level of
complexity to cellular dNTP metabolism (29). The activity of this
carrier protein may make cytoplasmic pools of dNTPs available to
mitochondria. This possibility is further strengthened by the mitochondrial toxicity observed with dideoxycytidine, a nucleoside analogue phosphorylated by cytoplasmic dCK (30). It seems that mammalian cells acquired several interdependent mechanisms that involve
multiple redundant activities for both nuclear and mitochondrial dNTP
supplies. The actual abundance and activities of these enzymes in
distinct cellular compartments may thus provide important regulatory means for the cell to accommodate different physiological requirements. Given the pharmacological importance of cellular deoxynucleoside kinases, additional studies aimed at the elucidation of the regulatory mechanisms that control their cell type-specific expression and subcellular location-dependent contribution to different
metabolic pathways are clearly warranted.
| |
FOOTNOTES |
|---|
* This work was supported in part by European Union Grant BIOMED BMH4-CT-96-0479 and the Greek General Secretariat for Science and Technology.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EMBL Data Bank with accession number(s) AJ133749 and AJ133750.
§ Supported by the Joint Graduate Program in Molecular Biology and Biomedicine of the Greek Ministry of Education.
To whom correspondence should be addressed. Tel.:
30-81-391173; Fax: 30-81-391101; E-mail:
talianid@nefeli.imbb.forth.gr.
| |
ABBREVIATIONS |
|---|
The abbreviations used are: dNTP, deoxynucleotide triphosphate; dCK, deoxycytidine kinase; dGK, deoxyguanosine kinase; mdGK, murine dGK; GFP, green fluorescent protein; TK, thymidine kinase; nt, nucleotide(s); bp, base pair(s).
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Reichard, P. (1988) Annu. Rev. Biochem. 57, 349-374[CrossRef][Medline] [Order article via Infotrieve] |
| 2. | Arner, E. S. J., and Eriksson, S. (1995) Pharmacol. Ther. 67, 155-186[CrossRef][Medline] [Order article via Infotrieve] |
| 3. |
Bianchi, V.,
Borella, S.,
Rampazzo, C.,
Ferraro, P.,
Calderazzo, F.,
Bianchi, L. C.,
Skog, S.,
and Reichard, P.
(1997)
J. Biol. Chem.
272,
16118-16124 |
| 4. |
Xu, Y.-Z.,
Huang, P.,
and Plunkett, W.
(1995)
J. Biol. Chem.
270,
631-637 |
| 5. | Wang, L., Hellman, U., and Eriksson, S. (1996) FEBS Lett. 390, 39-43[CrossRef][Medline] [Order article via Infotrieve] |
| 6. |
Johansson, M.,
and Karlsson, A.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
7258-7262 |
| 7. |
Johansson, M.,
and Karlsson, A.
(1997)
J. Biol. Chem.
272,
8454-8458 |
| 8. | Wang, L., Munch-Petersen, B., Sjoberg, A. H., Hellman, U., Bergman, T., Jornvall, H., and Eriksson, S. (1999) FEBS Lett. 443, 170-174[CrossRef][Medline] [Order article via Infotrieve] |
| 9. |
Wang, L.,
Karlsson, A.,
Arner, E. S. J.,
and Eriksson, S.
(1993)
J. Biol. Chem.
268,
22847-22852 |
| 10. | Zhu, C., Johansson, M., Permert, J., and Karlsson, A. (1998) Biochem. Pharmacol. 15, 1035-1040 |
| 11. |
Sjoberg, A. H.,
Wang, L.,
and Eriksson, S.
(1998)
Mol. Pharmacol.
53,
270-273 |
| 12. | Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual , 2nd Ed. , Cold Spring Harbor Laboratory, Cold Spring Harbor, NY |
| 13. | Kritis, A. A., Argyrokastritis, A., Moschonas, N. K., Power, S., Katrakili, N., Zannis, V. I., Cereghini, S., and Talianidis, I. (1996) Gene (Amst.) 173, 275-280[CrossRef][Medline] [Order article via Infotrieve] |
| 14. | Wang, J., and Eriksson, S. (1996) Antimicrob. Agents Chemother. 40, 1555-1557[Abstract] |
| 15. |
Ktistaki, E.,
Ktistakis, N. T.,
Papadogeorgaki, E.,
and Talianidis, I.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
9876-9880 |
| 16. | Eriksson, S., and Wang, L. (1997) Nucleosides Nucleotides 16, 653-659 |
| 17. | Neupert, W. (1994) Clin. Investig. 72, 251-261[Medline] [Order article via Infotrieve] |
| 18. |
Hendrick, J. P.,
Hodges, P. E.,
and Rosenberg, L. E.
(1989)
Proc. Natl. Acad. Sci. U. S. A.
86,
4056-4060 |
| 19. | Rizzuto, R., Brini, M., Pizzo, P., Murgia, M., and Pozzan, T. (1995) Curr. Biol. 5, 635-642[CrossRef][Medline] [Order article via Infotrieve] |
| 20. |
Yano, M.,
Kanazawa, M.,
Terada, K.,
Namchai, C.,
Yamaizumi, M.,
Hanson, B.,
Hoogenraad, N.,
and Mori, M.
(1997)
J. Biol. Chem.
272,
8459-8465 |
| 21. | Habteyesus, A., Nordenskjold, A., Bohman, C., and Eriksson, S. (1991) Biochem. Pharmacol. 42, 1829-1836[CrossRef][Medline] [Order article via Infotrieve] |
| 22. |
Karlsson, A.,
Johansson, M.,
and Eriksson, S.
(1994)
J. Biol. Chem.
269,
24374-24378 |
| 23. |
Bradshaw, H. D.,
and Deininger, P. L.
(1984)
Mol. Cell. Biol.
4,
2316-2320 |
| 24. |
Balasubramaniam, N. K.,
Veerisetty, V.,
and Gentry, G. A.
(1990)
J. Gen. Virol.
71,
2979-2987 |
| 25. | Brown, D. G., Visse, R., Sandhu, G., Davies, A., Rizkallah, P. J., Melitz, C., Summers, W. C., and Sanderson, M. R. (1995) Nat. Struct. Biol. 2, 876-881[CrossRef][Medline] [Order article via Infotrieve] |
| 26. |
Zhu, C.,
Johansson, M.,
Permert, J.,
and Karlsson, A.
(1998)
J. Biol. Chem.
273,
14707-14711 |
| 27. |
Johansson, M.,
Brismar, S.,
and Karlsson, A.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
11941-11945 |
| 28. |
Hatzis, P.,
Al-Madhoon, A. S.,
Jullig, M.,
Petrakis, T. G.,
Eriksson, S.,
and Talianidis, I.
(1998)
J. Biol. Chem.
273,
30239-30243 |
| 29. |
Bridges, E. G.,
Jiang, Z.,
and Cheng, Y.
(1999)
J. Biol. Chem.
274,
4620-4625 |
| 30. |
Chang, C. N.,
Skalski, V.,
Zhou, J. H.,
and Cheng, Y. C.
(1992)
J. Biol. Chem.
267,
22414-22420 |
This article has been cited by other articles:
![]() |
W. Lewis Defective mitochondrial DNA replication and NRTIs: pathophysiological implications in AIDS cardiomyopathy Am J Physiol Heart Circ Physiol, January 1, 2003; 284(1): H1 - H9. [Full Text] [PDF] |
||||
![]() |
A. H. Sjöberg, L. Wang, and S. Eriksson Antiviral Guanosine Analogs as Substrates for Deoxyguanosine Kinase: Implications for Chemotherapy Antimicrob. Agents Chemother., March 1, 2001; 45(3): 739 - 742. [Abstract] [Full Text] |
||||
![]() |
M. Jullig and S. Eriksson Apoptosis Induces Efflux of the Mitochondrial Matrix Enzyme Deoxyguanosine Kinase J. Biol. Chem., June 22, 2001; 276(26): 24000 - 24004. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |